Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
May 30, 2024 16:05 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty
May 28, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
– Royalty Pharma to Acquire Rights to Agios’ 15% Royalty on Potential Vorasidenib U.S. Net Sales for $905 Million Upfront upon FDA Approval of Vorasidenib; Agios to Share in Economics Above Certain...
Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress
May 14, 2024 10:00 ET
|
Agios Pharmaceuticals, Inc.
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional Presentations to Highlight Quality of Life Data from...
Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024
May 06, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024
May 03, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios Reports Business Highlights and First Quarter 2024 Financial Results
May 02, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
– Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 – – Announced Positive Results from the...
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
April 18, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
April 09, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
March 05, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
February 22, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024